Cargando…

2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?

BACKGROUND: Invasive fungal infections (IFI) are a known complication in aHSCT patients. Risk factors for IFI post aHSCT include history of IFI, high intensity conditioning regimens, prolonged neutropenia, and degree of donor matching. Guidelines recommend anti-Candida prophylaxis in low risk patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perreault, Sarah, Schiffer, Molly, Roeder, Heidi, McManus, Dayna, Topal, Jeffrey E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678736/ http://dx.doi.org/10.1093/ofid/ofad500.2348

Ejemplares similares

2694. Incidence of Pneumocytis jiroveci (PJP) Infection with 3-Month Prophylaxis of Aerosolized Pentamidine (AP) in Autologous Hematopoietic Stem Cell Transplantation (HSCT)
por: Perreault, Sarah, et al.
Publicado: (2019)

Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC)
por: López-Sánchez, Cristina, et al.
Publicado: (2020)

SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
por: Lindsay, Julian, et al.
Publicado: (2021)

Antifungal Prophylaxis
por: Johnson, Douglas Clark, et al.
Publicado: (2021)

2487. Vaccination Rates in Post-Transplant Hematopoietic Stem Cell Transplant (HSCT) Patients: Where Do We Stand?
por: Ahmad, Hiba, et al.
Publicado: (2018)

Reply: Antifungal Prophylaxis
por: Pennington, Kelly M., et al.
Publicado: (2021)

577. Incidence and Outcomes of Positive Outpatient Surveillance Blood Cultures in Hematopoietic Stem Cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose ≥ 0.5 mg/kg/day (HD) and Low Dose < 0.5mg/kg/day (LD) Steroid Therapy
por: Perreault, Sarah, et al.
Publicado: (2020)

1734. Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience in Colombia
por: Estacio, Mayra, et al.
Publicado: (2019)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

Antifungal Prophylaxis in Immunocompromised Patients
por: Vazquez, Lourdes
Publicado: (2016)

Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis
por: Döring, Michaela, et al.
Publicado: (2012)

aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis
por: Häußler, Vivien, et al.
Publicado: (2021)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

574. De-escalation of Broad Spectrum Antibiotics during Cytokine Release Syndrome with Haploidentical Hematopoietic Stem Cell Transplantation
por: Schiffer, Molly, et al.
Publicado: (2020)

Antifungal prophylaxis in critically ill patients
por: Silvestri, Luciano, et al.
Publicado: (2008)

729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients
por: Perreault, Sarah, et al.
Publicado: (2020)

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011)

Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
por: Takpradit, Chayamon, et al.
Publicado: (2021)

1150. Evaluating the Impact of Antibiotic Prophylaxis on the Microbiology and Incidence of Ventriculitis in Patients with External Ventricular Drains
por: McCormick, Jack, et al.
Publicado: (2019)

Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation
por: Lehrnbecher, Thomas, et al.
Publicado: (2023)

Reduced prefrontal cortex and sympathetic nervous system activity correlate with fatigue after aHSCT
por: Boberg, Erik, et al.
Publicado: (2021)

Current evidence of antifungal prophylaxis and therapy in pediatric patients
por: Giacchino, Mareva, et al.
Publicado: (2011)

Clinical practice update of antifungal prophylaxis in immunocompromised children
por: Ramos, José Tomás, et al.
Publicado: (2019)

Micafungin as antifungal prophylaxis in non-transplanted haemotological patients
por: Villaescusa, Teresa, et al.
Publicado: (2020)

Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients
por: Bow, Eric J, et al.
Publicado: (2015)

Posaconazole oral suspension for secondary antifungal prophylaxis in allogeneic stem cell transplantation recipients: a retrospective study
por: Ye, Peipei, et al.
Publicado: (2022)

Economic considerations of antifungal prophylaxis in patients undergoing surgical procedures
por: Cataldo, Maria Adriana, et al.
Publicado: (2011)

Fosfluconazole for Antifungal Prophylaxis in Very Low Birth Weight Infants
por: Takahashi, Daijiro, et al.
Publicado: (2009)

Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people
por: Awotiwon, Ajibola A, et al.
Publicado: (2018)

Diagnosis and Antifungal Prophylaxis for COVID-19 Associated Pulmonary Aspergillosis
por: Hawes, Armani M., et al.
Publicado: (2022)

Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients
por: Lehrnbecher, Thomas, et al.
Publicado: (2020)

Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
por: Riedel, Amy, et al.
Publicado: (2007)

Primary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damage
por: Gedik, Habip, et al.
Publicado: (2014)

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015)

Benefits of risk‐adapted and mould‐specific antifungal prophylaxis in childhood leukaemia
por: Meryk, Andreas, et al.
Publicado: (2020)

Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections
por: Brunet, Kévin, et al.
Publicado: (2022)

Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study
por: Gao, Lei, et al.
Publicado: (2016)

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation
por: Döring, Michaela, et al.
Publicado: (2012)

High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience
por: Kabut, Tomáš, et al.
Publicado: (2023)

Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Tafazoli, Ali, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0ge6rl8u57t21o513up5me89qi